In terms of cost, I think it's honestly something we're not talking about. We are in the midst of a revolution of highly effective and highly expensive new genetic drug treatments and just general drug treatments, including genetic drug treatments. GLP1s are the tip of the iceberg.Insurers are going to face some very difficult decisions about drugs which are really miraculous, doing incredible things, but are also very expensive. In terms of coverage, the most acute problem is the expiration of the subsidie ...